Emergent BioSolutions
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 1.6K
- Market Cap
- -
- Introduction
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units ...
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 105
- Registration Number
- NCT01263691
- Locations
- 🇺🇸
North Carolina Clinical Research, Raleigh, North Carolina, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
🇺🇸Jean Brown Research, Salt Lake City, Utah, United States
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 50
- Registration Number
- NCT01202695
- Locations
- 🇺🇸
ICON Development Solutions, San Antonio, Texas, United States
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 25
- Registration Number
- NCT01158157
- Locations
- 🇺🇸
Cangene Plasma Resources, Mid-Florida, Altamonte Springs, Florida, United States
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
- Conditions
- Interventions
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 166
- Registration Number
- NCT01006798
- Locations
- 🇺🇸
The Center for Pharmaceutical Research, Kansas City, Missouri, United States
🇺🇸Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States
🇺🇸University of Rochester, Rochester, New York, United States
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
- Conditions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 14108
- Registration Number
- NCT00928577
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 897227
- Registration Number
- NCT00927719
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 5
- Registration Number
- NCT00893516
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 21
- Registration Number
- NCT00877656
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 129
- Registration Number
- NCT00845650
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center Inc., Baltimore, Maryland, United States
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 187
- Registration Number
- NCT00679172
- Locations
- 🇺🇸
John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
🇺🇸Unit of Infectious Diseases, University of Vermont College of Medicine, Burlington, Vermont, United States
🇺🇸Miami Research Associates, South Miami, Florida, United States